| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA646: Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) |
|
Medicine details |
|
| Medicine name | glasdegib (Daurismo®) |
| Formulation | 25 mg and 100 mg film-coated tablets |
| Reference number | 3661 |
| Indication | In combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy |
| Company | Pfizer Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/09/2020 |
| NICE guidance | TA646: Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) |